[1] |
Scarisbrick JJ, Quaglino P, Prince HM, et al. The PROCLIPI international registry of early⁃stage mycosis fungoides identifies substantial diagnostic delay in most patients[J]. Br J Dermatol, 2019,181(2):350⁃357. doi: 10.1111/bjd.17258.
|
[2] |
Salhany KE, Cousar JB, Greer JP, et al. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study[J]. Am J Pathol, 1988,132(2):265⁃277.
|
[3] |
Aulasevich N, Haist M, Försch S, et al. The role of the immune phenotype in tumor progression and prognosis of patients with mycosis fungoides: a quantitative immunohistology whole slide approach[J]. Cells, 2022,11(22):3570. doi: 10.3390/cells112 23570.
|
[4] |
Diamandidou E, Colome⁃Grimmer M, Fayad L, et al. Transformation of mycosis fungoides/Sézary syndrome: clinical characteristics and prognosis[J]. Blood, 1998,92(4):1150⁃1159. PMID: 9694702.
|
[5] |
Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO⁃EORTC classification for primary cutaneous lymphomas[J]. Blood, 2019,133(16):1703⁃1714. doi: 10.1182/blood⁃2018⁃11⁃881268.
|
[6] |
Oh Y, Stoll JR, Moskowitz A, et al. Primary cutaneous T⁃cell lymphomas other than mycosis fungoides and Sézary syndrome. Part Ⅱ: prognosis and management[J]. J Am Acad Dermatol, 2021,85(5):1093⁃1106. doi: 10.1016/j.jaad.2021.04.081.
|
[7] |
Shinohara MM, Shustov A. How I treat primary cutaneous CD30(+) lymphoproliferative disorders[J]. Blood, 2019,134(6):515⁃524. doi: 10.1182/blood.2019000785.
|
[8] |
Kadin ME, Hughey LC, Wood GS. Large⁃cell transformation of mycosis fungoides⁃differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium[J]. J Am Acad Dermatol, 2014,70(2):374⁃376. doi: 10.1016/j.jaad.2013.09.007.
|
[9] |
Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides[J]. J Am Acad Dermatol, 2005,53(6):1053⁃1063. doi: 10.1016/j.jaad.2005.08.057.
|
[10] |
张莹, 甘璐, 李思琪, 等. 伴大细胞转化的蕈样肉芽肿24例临床病理及免疫表型分析[J]. 中华皮肤科杂志, 2022,55(1):20⁃26. doi: 10.35541/cjd.20210116.
|
[11] |
Gao C, McCormack CJ, van der Weyden C, et al. The importance of differentiating between mycosis fungoides with CD30⁃positive large cell transformation and mycosis fungoides with coexistent primary cutaneous anaplastic large cell lymphoma[J]. J Am Acad Dermatol, 2021,84(1):185⁃187. doi: 10.1016/j.jaad.2020. 04.073.
|
[12] |
O′Donnell M, Zaya R, Correia E, et al. Disease characteristics, prognosis, and response to therapy in patients with large⁃cell transformed mycosis fungoides: a single⁃center retrospective study[J]. J Am Acad Dermatol, 2022,86(6):1285⁃1292. doi: 10.1016/j.jaad.2021.07.013.
|
[13] |
Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal[J]. J Clin Oncol, 2010,28(31):4730⁃4739. doi: 10.1200/JCO.2009.27.7665.
|
[14] |
Fauconneau A, Pham⁃Ledard A, Cappellen D, et al. Assessment of diagnostic criteria between primary cutaneous anaplastic large⁃cell lymphoma and CD30⁃rich transformed mycosis fungoides; a study of 66 cases[J]. Br J Dermatol, 2015,172(6):1547⁃1554. doi: 10.1111/bjd.13690.
|
[15] |
Collins K, Gu J, Aung PP, et al. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30⁃positive T cell lymphoproliferative disorders?[J]. Virchows Arch, 2021,479(2):377⁃383. doi: 10.1007/s00428⁃021⁃03056⁃y.
|